NASHVILLE, Tenn.--(BUSINESS WIRE)--Reimagine Care, the nation’s leading provider of virtual-first cancer care, proudly announces the expansion of its esteemed Clinical Advisory Board with the appointment of renowned healthcare professionals with expertise in care across the cancer continuum. Comprised of distinguished leaders, the board is poised to provide strategic guidance and insight to further enhance Reimagine Care's innovative solutions.
Led by Medical Director, Dr. Pallav Mehta, the Clinical Advisory Board brings together a diverse group of experts with extensive experience across multiple oncology disciplines, including nursing, specialty medicine, policy, and health technology. Their collective expertise will play a pivotal role in steering Reimagine Care towards even greater success in its mission to transform healthcare delivery and improve patient outcomes.
"We are delighted to welcome such a talented and acclaimed group of professionals to our Clinical Advisory Board," said Dan Nardi, CEO of Reimagine Care. "Their depth of knowledge and breadth of experience will be invaluable as we continue to develop solutions to address the evolving needs of patients with cancer and their providers."
Dr. Pallav Mehta, Medical Director for Reimagine Care shares, “Each member of the Clinical Advisory Board brings a unique perspective and set of skills that will enrich Reimagine Care's strategic decision-making process and ensure the company remains at the forefront of virtual-first cancer care.”
The Clinical Advisory Board will include:
Yousuf Zafar, MD, MHS - Dr. Yousuf Zafar is a practicing oncologist with more than 20 years of clinical, research, and healthcare administration experience. He is driven to optimize patient outcomes while lowering healthcare costs. Dr. Zafar has most recently served in leadership roles in the healthcare technology industry. Prior to that, he was a professor of medicine and chief quality and innovation officer at the Duke Cancer Institute. He has over 120 peer-reviewed publications. Dr. Zafar completed his internal medicine residency at the University of Cincinnati Medical Center and his medical oncology fellowship at the Duke University Medical Center. He earned a master’s degree in clinical research at Duke. He is a Fellow of the American Society of Clinical Oncology and an adjunct professor at the Duke University School of Medicine.
Robert Hauser, PharmD, PhD - Dr. Robert Hauser is the Co-Founder and Chief Business Development & Analytics Officer for Vidence. His responsibilities include identifying business opportunities to leverage a growing volume of deep longitudinal clinical-genomic data for use in multiple healthcare channels including biopharmaceutical, provider and payer markets. His prior role was Vice President of Clinical Analytics and HEOR at Cancer Treatment Centers of America. Prior to joining CTCA, Rob was the Senior Director of External Relations and Business Development for CancerLinQ at the American Society of Clinical Oncology.
Dr. Hauser has more than 25 years of progressively responsible experience in health economic and strategy planning services related to clinical trial development, oncology registries, EMR systems, informatics, and business development. Prior to joining ASCO, he was the Director of Operations and Informatics at the International Oncology Network (ION), and was responsible for developing strategy for the use of informatics data, providing analytics for Oncology Managed Care Initiatives, developing proposals, budgets, and the execution of projects from inception to completion.
Dr. Hauser has led more than 25 research activities, has over 10 peer reviewed publications, served as guest editor and has presented hundreds of times to audiences large and small. He currently serves on the Board of Directors for the Geriatric Oncology Consortium, the Board of Directors for Share for Cures and serves on the Advisory Board of Doctors Helping Doctors Transform Healthcare. In the past he has helped shape oncology EHR use through his appointment on the CCHIT Oncology Work Group in 2010-11.
Shelley Fuld Nasso, MPP – As Chief Executive Officer, Shelley Fuld Nasso leads the public policy activities of National Coalition for Cancer Survivorship (NCCS) at a time of rapid and fundamental health care system change. Shelley joined NCCS in December 2012 and was named CEO in October 2013.
Prior to joining NCCS, Ms. Nasso served in leadership roles at Susan G. Komen, where she leveraged Komen’s grassroots network in Washington, D.C., and in state capitals. There she built relationships with policymakers and partner organizations and led a team of staff and volunteer leaders to influence state budgets and legislation. Ms. Nasso witnessed first-hand the strengths and flaws of the cancer care system and embraces the notion that policy change can make cancer care better for patients and caregivers.
“I am honored to join Reimagine Care’s Clinical Advisory Board. I look forward to bringing the perspectives of patients to this effort to revolutionize patient care through technology," said Shelley Fuld Nasso, MPP. She continues, “I am pleased to be part of a collaboration aimed at advancing meaningful improvements in cancer care delivery.”
The expansion of the Clinical Advisory Board marks a significant milestone for Reimagine Care as it continues to expand its reach and influence in the healthcare industry. With the guidance and expertise of these admired healthcare leaders, Reimagine Care is poised to make even greater strides in its pursuit of transforming the future of healthcare.
For more information about Reimagine Care, please visit www.reimaginecare.com.
About Reimagine Care:
We believe people living with cancer deserve a better patient experience; to feel their best and to spend as much time as possible with the people they love, doing the things that bring them joy. Reimagine Care integrates clinical oncology experts and robust, enabling technologies to deliver a high-touch, individualized cancer treatment and recovery experience. This holistic approach relies on the combination of empathy and knowledge of our clinical care team with our thoughtfully designed and easy-to-use platform.
Our vision and our approach fuel the delivery of high-quality, safe, home-centered, coordinated cancer care that makes care more patient-centric, accessible, affordable, and the first choice for patients everywhere.
Extending Care Beyond the Clinic.
